Net income
-84.2 million USD
2025-07-01 – 2026-06-30
Fundies. English
Alto Neuroscience, Inc.
EDGAR18 filing records in this dataset, filed from 2023-11-27 to 2026-08-12. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 244 million USD Source
Exact value
243733000 USD
- Long-term debt including current maturities
- 16.2 million USD Derived
- Shares outstanding
- 35.1 million shares Source
Exact value
35093940 shares
Reported share-count change
29.63% · 8.02 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-68.3 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -40253000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -30335000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -51769000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -40253000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -27091000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -46851000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -27091000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
556 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 556000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 556000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 556000 USD · 2026-01-01 – 2026-03-31 Source
Free cash flow
-68.8 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -40253000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -30335000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -51769000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -40253000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -27091000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -46851000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -27091000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 556000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 556000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 556000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-12.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2025-12-31
- Total assets: 3 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 3 of 11 periods available· newest 2025-12-31
- Current liabilities: 3 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2024-12-31
- Shares outstanding: 3 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 1.81 millionPrior period
−USD 61.43 million
–
Current period
−USD 63.24 million
–
Exact inputs and evidence
-63238000 − -61431000 = -1807000 USD
-61431000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-63238000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 4.35 millionPrior period
−USD 47.42 million
–
Current period
−USD 51.77 million
–
Exact inputs and evidence
-51769000 − -47424000 = -4345000 USD
-47424000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-51769000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-98.8%Prior period
USD 2.08 million
–
Current period
USD 24,000
–
Exact inputs and evidence
24000 − 2075000 = -2051000 USD
2075000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source24000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 36.31 million Exact valueExact value: -36305000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 33.45 million Exact valueExact value: -33448000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 470,000 Exact valueExact value: 470000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 33.92 million Calculation and evidence-33448000 − 470000 USD Exact free cash flow: -33918000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 61.43 million Exact valueExact value: -61431000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 47.42 million Exact valueExact value: -47424000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.08 million Exact valueExact value: 2075000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 49.5 million Calculation and evidence-47424000 − 2075000 USD Exact free cash flow: -49499000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 63.24 million Exact valueExact value: -63238000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 51.77 million Exact valueExact value: -51769000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 24,000 Exact valueExact value: 24000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 51.79 million Calculation and evidence-51769000 − 24000 USD Exact free cash flow: -51793000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
18 filings · 737 latest values · 737 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001999480, 1999480, ANRO, edgar:1999480
Also known as Alto Neuroscience, Inc.